Evaluation of the impact of effective compounds of Teucrium Chamaedrys on visual function indices in patients with COVID-19.

Production of Effective Combinations of Terpenoids and Flavonoids of Teucrium Chamaedrys Extract and Evaluation of its Effect on Visual Function Indices in Patients with COVID-19.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211223053497N1

Enrollment

132

Registered

2022-01-04

Start date

2022-01-15

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Patients with COVID-19 that receiving 0.04% eye drops containing the effective combination of flavonoids and terpenoids for one week. Intervention 2: Control group:

Eligibility

Sex/Gender

All

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: The age of the participants is between 25 to 40 years old Positive results of Real-time PCR tests (positive nasopharyngeal and oropharyngeal swab samples) With symptoms of decreased visual acuity, fluctuating or wavy vision, and or inflammation of the ocular conjunctiva when visiting the hospital

Exclusion criteria

Exclusion criteria: History of underlying systemic diseases such as diabetes History of eye diseases, especially retinal lesions Best corrected visual acuity less than 20/30 History of cataract surgery History of various types of manifest deviations (strabismus) and amblyopia Use of drugs affecting the structure and function of the retina and visual system such as hydroxychloroquine

Design outcomes

Primary

Measure	Time frame
Contrast sensitivity. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through the Pelli-Robson contrast sensitivity chart with a size of 59 × 84 at a distance of 1 meter.;Heterophoria ( latent squint). Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Using the cover test method with the prism at near and far distances.;Near point of accommodation. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through push-up test and applying accommodative targets in monocular and binocular situations.;Accommodative facility. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Using a flipper lens with power of +/- 2.00 diopters in the form of binoculars at a distance of 40 cm.;Fusional vergence amplitudes. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Using the horizontal prisms at near and far distances through step method.;Fusional vergence facility. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Using flipper prisms with values of 3 and 12 prisms binocularly at a distance of 40 cm.;Near point of convergence. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through push-up test and applying accommodative targets binocularly.;Visual acuity. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through the Snellen chart at a distance of 6 meters and 40 centimeters.;Color vision. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through the 24-plate color vision booklet of the Ishihara at a distance of 70 cm.;Depth pe	—

Measure

Time frame

Contrast sensitivity. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through the Pelli-Robson contrast sensitivity chart with a size of 59 × 84 at a distance of 1 meter.;Heterophoria ( latent squint). Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Using the cover test method with the prism at near and far distances.;Near point of accommodation. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through push-up test and applying accommodative targets in monocular and binocular situations.;Accommodative facility. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Using a flipper lens with power of +/- 2.00 diopters in the form of binoculars at a distance of 40 cm.;Fusional vergence amplitudes. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Using the horizontal prisms at near and far distances through step method.;Fusional vergence facility. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Using flipper prisms with values of 3 and 12 prisms binocularly at a distance of 40 cm.;Near point of convergence. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through push-up test and applying accommodative targets binocularly.;Visual acuity. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through the Snellen chart at a distance of 6 meters and 40 centimeters.;Color vision. Timepoint: Before the intervention and 7 and 14 days after the start of the intervention. Method of measurement: Through the 24-plate color vision booklet of the Ishihara at a distance of 70 cm.;Depth pe

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasoul Amini Vishteh

Artesh University of Medical Sciences

ra.am136@yahoo.com+98 21 8802 8350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026